4,4'-Dihydroxybenzophenone-2,4-dinitrophenylhydrazone (A-007): a topical treatment for cutaneous metastases from malignant cancers
| Autor: | Leonard Thomas, Edward T. Krementz, Karl Tornyos, Andrew H. Rodgers, Steven Parker, Lee Roy Morgan, Catherine L. Hooper, David Eilender, Catherine McCormick, Patricia LoRusso |
|---|---|
| Rok vydání: | 2005 |
| Předmět: |
Adult
Male Cancer Research medicine.medical_specialty Skin Neoplasms medicine.medical_treatment Administration Topical Antineoplastic Agents Toxicology Metastasis Breast cancer Phenols medicine Humans Multicenter Studies as Topic Pharmacology (medical) Angiosarcoma Aged Pharmacology Aged 80 and over business.industry Melanoma Hydrazones Cancer Middle Aged medicine.disease Rash Dermatology Surgery Radiation therapy Oncology Female Sarcoma medicine.symptom business |
| Zdroj: | Cancer chemotherapy and pharmacology. 57(6) |
| ISSN: | 0344-5704 |
| Popis: | Purpose: This study is to document the activity and acceptability for a new topical agent, A-007, in the treatment of cutaneous metastases from cancer. Patients and methods: This is a multicenter study involving 27 patients with inoperable skin lesions from histologically confirmed cancers of the breast and oral cavity, non-Hodgkin’s lymphoma, Kaposi’s sarcoma, and angiosarcoma that had failed radiotherapy or systemic treatment. A-007, as a 0.25% gel, was applied twice daily to the areas of cancer to be measured as well as applied to a healthy control area distant from the cancer areas. An untreated cancer area was also included and documented as a cancer control. Results: The overall objected response rate with A-007 was 26%, with an additional 19% minimum response/stabilization of cancer. For patients with breast cancer, hormonal status did not have an impact on response. The median duration of response was 15 weeks (with one patient having a response for 3.5 years). Toxicities observed were itching, burning, and a rash, in 6 of the 27 patients. The skin toxicities were in the cancer-treated fields; none were observed in the A-007 control areas. All irritated areas cleared while continuing treatment, and the tumor lesions in the areas of itching also improved. Conclusion: A-007, as a 0.25% gel, is confirmed as an effective palliative treatment option for cutaneous metastases from cancers. Skin reactions were minimal, tolerated, and no cessation of treatment was required. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full text from SpringerLink